Omeprazole - Generic Drug Details

What are the generic drug sources for omeprazole and what is the scope of patent protection?

Omeprazole is the generic ingredient in eight branded drugs marketed by Actavis Labs Fl Inc, Apotex, Aurobindo Pharma, Breckenridge, Dr Reddys Labs Ltd, Glenmark Pharms Ltd, Hetero Labs Ltd Iii, Impax Labs, Lannett Co Inc, Lupin Ltd, Pharmobedient, Sandoz, Strides Pharma, Teva Pharms Usa, Xiromed, Zydus Pharms Usa Inc, Astrazeneca, Dexcel Pharma, Dr Reddys, Sun Pharm, Dexcel, Aurobindo Pharma Ltd, Spil, Covis, Marksans Pharma, P And L, Perrigo R And D, Ajanta Pharma Ltd, Anda Repository, Aurolife Pharma Llc, Chartwell Rx, Sciegen Pharms, Strides Pharma Intl, Zydus, Zydus Pharms, Salix, Riley Consumer, Azurity, and Novitium Pharma, and is included in fifty-six NDAs. There are ten patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Omeprazole has four patent family members in three countries.

There are one hundred and thirty-one drug master file entries for omeprazole. Ninety-two suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for omeprazole

International Patents:	4
US Patents:	10
Tradenames:	8
Applicants:	39
NDAs:	56
Drug Master File Entries:	131
Finished Product Suppliers / Packagers:	92
Raw Ingredient (Bulk) Api Vendors:	144
Clinical Trials:	493
Patent Applications:	6,855
Drug Prices:	Drug price trends for omeprazole
Drug Sales Revenues:	Drug sales revenues for omeprazole
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for omeprazole
What excipients (inactive ingredients) are in omeprazole?	omeprazole excipients list
DailyMed Link:	omeprazole at DailyMed

See drug prices for omeprazole

See drug sales revenues for omeprazole

Recent Clinical Trials for omeprazole

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rehman Medical Institute - RMI	PHASE4
Tanta University	PHASE3
Shandong Suncadia Medicine Co., Ltd.	PHASE1

See all omeprazole clinical trials

Generic filers with tentative approvals for OMEPRAZOLE

Applicant	Application No.	Strength	Dosage Form
		40MG	CAPSULE, DELAYED REL PELLETS;ORAL
		20MG	CAPSULE, DELAYED REL PELLETS;ORAL
		10MG	CAPSULE, DELAYED REL PELLETS;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for omeprazole

Drug Class	Proton Pump Inhibitor
Mechanism of Action	Cytochrome P450 2C19 Inhibitors Proton Pump Inhibitors

Medical Subject Heading (MeSH) Categories for omeprazole

Anti-Ulcer Agents

Proton Pump Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for omeprazole

A02BC	Proton pump inhibitors
A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A02	DRUGS FOR ACID RELATED DISORDERS
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for OMEPRAZOLE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OMEPRAZOLE	Delayed-release Tablets	omeprazole	20 mg	022032	1	2015-06-03

US Patents and Regulatory Information for omeprazole

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus Pharms Usa Inc	OMEPRAZOLE	omeprazole	CAPSULE, DELAYED REL PELLETS;ORAL	091352-001	Nov 19, 2012	AB	RX	No	No
Glenmark Pharms Ltd	OMEPRAZOLE	omeprazole	CAPSULE, DELAYED REL PELLETS;ORAL	091672-003	Oct 31, 2014	AB	RX	No	No
Ajanta Pharma Ltd	OMEPRAZOLE AND SODIUM BICARBONATE	omeprazole; sodium bicarbonate	FOR SUSPENSION;ORAL	205545-002	Jul 27, 2016	AB	RX	No	Yes
Dexcel	OMEPRAZOLE MAGNESIUM	omeprazole magnesium	CAPSULE, DELAYED RELEASE;ORAL	216096-001	May 24, 2022		OTC	No	No
Azurity	KONVOMEP	omeprazole; sodium bicarbonate	FOR SUSPENSION;ORAL	213593-001	Aug 30, 2022		RX	Yes	Yes	11,103,492		Y

Expired US Patents for omeprazole

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca	PRILOSEC	omeprazole	CAPSULE, DELAYED REL PELLETS;ORAL	019810-001	Sep 14, 1989	4,786,505*PED
Astrazeneca	PRILOSEC	omeprazole	CAPSULE, DELAYED REL PELLETS;ORAL	019810-001	Sep 14, 1989	6,166,213*PED
Astrazeneca	PRILOSEC	omeprazole	CAPSULE, DELAYED REL PELLETS;ORAL	019810-002	Jan 15, 1998	6,150,380*PED
Astrazeneca	PRILOSEC	omeprazole	CAPSULE, DELAYED REL PELLETS;ORAL	019810-003	Oct 5, 1995	6,191,148*PED
Astrazeneca	PRILOSEC	omeprazole	CAPSULE, DELAYED REL PELLETS;ORAL	019810-003	Oct 5, 1995	4,255,431*PED

International Patents for omeprazole

Country	Patent Number	Title	Estimated Expiration
Australia	2017285390	Stable orally disintegrating pharmaceutical compositions
World Intellectual Property Organization (WIPO)	2017216789
European Patent Office	3932396	COMPOSITIONS PHARMACEUTIQUES STABLES À DÉSINTÉGRATION ORALE (STABLE ORALLY DISINTEGRATING PHARMACEUTICAL COMPOSITIONS)
European Patent Office	3932396	COMPOSITIONS PHARMACEUTIQUES STABLES À DÉSINTÉGRATION ORALE (STABLE ORALLY DISINTEGRATING PHARMACEUTICAL COMPOSITIONS)
Australia	2017285390	Stable orally disintegrating pharmaceutical compositions

Supplementary Protection Certificates for omeprazole

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0124495	SPC/GB01/006	United Kingdom		PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727
0984957	SPC/GB11/013	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
1411900	2011C/016	Belgium		PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214
0984957	2012/048	Ireland		PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812
1411900	2011/016	Ireland		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105

Market Dynamics and Financial Trajectory for Omeprazole

Last updated: February 20, 2026

Omeprazole, a proton pump inhibitor (PPI), primarily treats acid-related gastrointestinal conditions. It remains a leading medication worldwide, driven by patent expirations, generics entry, and increasing demand for acid suppression therapy.

Market Overview

The Global Omeprazole Market was valued at approximately USD 6.4 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4.2% from 2023 to 2030, reaching around USD 8.7 billion by 2030.[1]

Major drivers include:

• Rise in gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome globally.
• Aging populations with increased susceptibility to acid-related disorders.
• Expansion of over-the-counter (OTC) markets, especially in North America and Europe.

Competition and Patent Landscape

The original patent for omeprazole expired in 2001 ([2]). Since then, multiple generics entered markets, drastically reducing prices. Major players in generics include:

• Mylan (now Viatris)
• Teva Pharmaceuticals
• Dr. Reddy’s Laboratories
• Jiangsu Hengrui Medicine

Despite patent loss, some formulations remain protected by secondary patents on specific formulations or delivery methods, delaying certain generic entries.

Market Segments

• Prescription Market: Accounts for approximately 60% of total revenue. It is driven by hospital and clinic prescriptions.
• OTC Market: Growing at 6% CAGR, primarily in mature markets, driven by self-medication trends.

Pricing Trends

Post-patent expiry, prices typically decline sharply. For omeprazole, generic prices dropped by up to 80% within two years in the U.S. ([3]). The price reduction impacted the revenue of branded formulations but increased market penetration.

Regional Market Analysis

Region	Market Share (2022)	Growth Rate (2023-2030)	Key Trends
North America	40%	3.8%	Fragmented, high OTC sales
Europe	25%	4.0%	Mature, strong generic competition
Asia-Pacific	20%	5.0%	Rapid growth, expanding healthcare coverage
Rest of the World	15%	4.5%	Emerging markets, increasing awareness of GI disorders

Revenue Projections

Year	Estimated Revenue (USD billion)	Notes
2022	6.4	Baseline
2025	7.2	Growth driven by OTC expansion
2030	8.7	Market stabilization with increased competition

Key Factors Influencing Future Trajectory

• Patent Litigation and Secondary Patents: Protects some formulations, delaying generic erosion in select markets.
• Pricing Pressure: Increased competition will continue to push down prices, especially outside the U.S.
• Regulatory Changes: Approval pathways for OTC versions and combination drugs impact sales.
• Innovative Delivery Forms: New formulations (e.g., injectable, sustained-release) could command premium pricing.
• Market Penetration: Growing adoption in emerging markets will sustain volume growth.

Financial Outlook for Developers and Manufacturers

• Generics manufacturers experience margins compressing from 55% pre-2010 to approximately 10-15% currently ([4]).
• Branded formulations retain higher margins but face patent challenges.
• Investment in OTC formulations and novel delivery mechanisms provides avenues for higher revenue streams.

Risks and Challenges

• Patent cliffs continue to pressure sales.
• Price wars distort market profitability.
• Regulatory hurdles for innovative formulations.
• Supply chain disruptions potentially affecting production.

Key Takeaways

• Omeprazole remains a foundational PPI with a stable, growing market driven by global GI disorder prevalence.
• Market growth is increasingly reliant on OTC sales, especially in mature markets.
• Price erosion due to generic competition remains significant, although secondary patents extend exclusivity in some contexts.
• Emerging markets provide growth opportunities through increasing healthcare access.
• Innovations in drug formulation could sustain higher profit margins.

FAQs

1. How does patent expiration impact the omeprazole market?
Patent expiration in 2001 led to a surge of generic entries, significantly lowering prices and shifting revenue from branded to generic manufacturers.

2. What are the main regions expected to drive future growth?
Asia-Pacific leads with a CAGR of approximately 5%, driven by expanding healthcare infrastructure. North America and Europe will see moderate growth, supported by OTC sales.

3. How have pricing trends evolved since patent expiry?
Generic prices declined by up to 80% within two years post-expiration, exerting downward pressure on overall revenue.

4. What opportunities exist in the OTC segment?
The OTC segment accounts for nearly 40% of global omeprazole revenue, with increasing consumer self-medication driven by broader availability and awareness.

5. Which innovation areas could influence the market’s future?
Development of new formulations, delivery methods, and combination therapies can help sustain higher margins amid intense competition.

---

References

[1] MarketResearch.com. (2023). Omeprazole market analysis report.
[2] U.S. Patent and Trademark Office. (2001). Patent expiration date for omeprazole.
[3] IMS Health. (2021). Price trends in proton pump inhibitors post-patent expiry.
[4] EvaluatePharma. (2022). Generic drug margins and market shifts.